Published in Immunotherapy Weekly, May 18th, 2005
This multicenter study was conducted by Guy Webster, MD, Thomas Jefferson University, Philadelphia, Pennsylvania; Robert Skidmore, MD, Gainesville, Florida; and Anna Duarte, MD, Children's Skin Center, Miami, Florida.
This was a small, phase II, proof-of-principle study that enrolled 13 patients who received either COL-3 or placebo for 28 days. Patients were evaluated at baseline and at days 14, 28, and 42. Inflammatory lesion counts and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.